ProQR Therapeutics (PRQR) Stock Price

ProQR Therapeutics Price

NASDAQ·CLOSED
1.78EUR+0.08 (+4.60 %)
Market closed

Revenue has compounded at 77.5% per year over the past 12 years to 19.55 M EUR. ProQR Therapeutics's net margin stands at -142.0%, up from -492.8% several years earlier. Analysts set a median price target of 8.39 EUR, implying 371.3% above the current price. Of 15 analysts, 14 rate the stock a buy — an overall Buy consensus. Over the past year ProQR Therapeutics shares have lost 13.2%. The stock trades about 46% above its 52-week low.

ProQR Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of ProQR Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how ProQR Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing ProQR Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

ProQR Therapeutics Stock Price History
DateProQR Therapeutics Price
7/30/20261.78 EUR
7/28/20261.70 EUR
7/24/20261.72 EUR
7/8/20261.68 EUR
6/22/20261.92 EUR
6/18/20261.91 EUR
6/5/20261.29 EUR
6/4/20261.32 EUR
6/3/20261.26 EUR
6/2/20261.26 EUR
6/1/20261.22 EUR
5/29/20261.36 EUR
5/28/20261.35 EUR
5/27/20261.34 EUR
5/26/20261.35 EUR
5/22/20261.34 EUR
5/21/20261.24 EUR
5/20/20261.23 EUR
5/19/20261.23 EUR
5/18/20261.30 EUR
5/15/20261.37 EUR
5/13/20261.45 EUR
5/4/20261.40 EUR
4/22/20261.75 EUR
4/21/20261.74 EUR
4/20/20261.84 EUR
4/16/20261.95 EUR
4/15/20261.99 EUR
4/14/20261.99 EUR
4/13/20261.80 EUR
4/9/20261.98 EUR
4/8/20261.83 EUR
4/7/20261.70 EUR
4/6/20261.81 EUR
4/2/20261.71 EUR
4/1/20261.71 EUR
3/31/20261.62 EUR
3/30/20261.51 EUR
3/27/20261.37 EUR
3/26/20261.50 EUR
3/25/20261.58 EUR
3/24/20261.49 EUR
3/23/20261.55 EUR
3/20/20261.54 EUR
3/19/20261.59 EUR
3/18/20261.72 EUR
3/17/20261.77 EUR
3/16/20261.76 EUR
3/13/20261.82 EUR
3/12/20261.72 EUR
3/11/20261.81 EUR
3/10/20261.80 EUR
3/9/20261.89 EUR
3/6/20261.78 EUR
3/5/20261.69 EUR
3/4/20261.70 EUR
3/3/20261.50 EUR
3/2/20261.58 EUR
2/27/20261.59 EUR
2/26/20261.59 EUR
2/25/20261.54 EUR
2/24/20261.51 EUR
2/23/20261.44 EUR
2/20/20261.44 EUR
2/19/20261.47 EUR
2/18/20261.49 EUR
2/17/20261.45 EUR
2/13/20261.46 EUR
2/12/20261.39 EUR
2/11/20261.42 EUR
2/10/20261.48 EUR
2/9/20261.47 EUR
2/6/20261.50 EUR
2/5/20261.46 EUR
2/4/20261.55 EUR
2/3/20261.59 EUR
2/2/20261.55 EUR
1/30/20261.62 EUR
1/29/20261.60 EUR
1/28/20261.62 EUR
1/27/20261.68 EUR
1/26/20261.69 EUR
1/23/20261.75 EUR
1/22/20261.71 EUR
1/21/20261.64 EUR
1/20/20261.68 EUR
1/16/20261.65 EUR
1/15/20261.58 EUR
1/14/20261.64 EUR
1/13/20261.64 EUR
1/12/20261.68 EUR
1/9/20261.77 EUR
1/8/20262.10 EUR
1/7/20262.16 EUR
1/6/20262.08 EUR
1/5/20262.04 EUR
1/2/20261.99 EUR
12/31/20252.02 EUR
12/30/20252.00 EUR
12/29/20252.04 EUR
12/26/20252.17 EUR
12/24/20252.17 EUR
12/23/20252.21 EUR
12/22/20252.14 EUR
12/19/20252.21 EUR
12/18/20252.10 EUR
12/17/20252.14 EUR
12/16/20252.27 EUR
12/15/20252.45 EUR
12/12/20252.33 EUR
12/11/20252.36 EUR
12/10/20252.23 EUR
12/9/20252.32 EUR
12/8/20252.12 EUR
12/5/20252.09 EUR
12/4/20252.12 EUR
12/3/20252.01 EUR
12/2/20251.95 EUR
12/1/20252.12 EUR
11/28/20252.34 EUR
11/26/20252.36 EUR
11/25/20252.15 EUR
11/24/20252.20 EUR
11/21/20252.06 EUR
11/20/20252.06 EUR
11/19/20252.03 EUR
11/18/20252.08 EUR
11/17/20252.05 EUR
11/14/20252.17 EUR
11/13/20252.16 EUR
11/12/20252.16 EUR
11/11/20252.16 EUR
11/10/20252.16 EUR
11/7/20252.22 EUR
11/6/20252.21 EUR
11/5/20252.38 EUR
11/4/20252.38 EUR
11/3/20252.59 EUR
10/31/20252.75 EUR
10/30/20252.72 EUR
10/29/20252.65 EUR
10/28/20252.85 EUR
10/27/20252.86 EUR
10/23/20252.82 EUR
10/22/20252.72 EUR
10/21/20252.95 EUR
10/20/20253.05 EUR
10/16/20252.80 EUR
10/15/20252.71 EUR
10/14/20252.46 EUR
10/13/20252.29 EUR
10/9/20252.50 EUR
10/8/20252.36 EUR
10/7/20252.27 EUR
10/6/20252.36 EUR
10/2/20252.25 EUR
10/1/20252.16 EUR
9/30/20252.13 EUR
9/29/20252.19 EUR
9/25/20252.07 EUR
9/24/20252.10 EUR
9/23/20252.16 EUR
9/22/20252.16 EUR
9/18/20252.19 EUR
9/17/20252.06 EUR
9/16/20251.99 EUR
9/15/20251.99 EUR
9/11/20252.19 EUR
9/10/20252.25 EUR
9/9/20252.33 EUR
9/8/20252.33 EUR
9/4/20252.39 EUR
9/3/20252.43 EUR
9/2/20252.29 EUR
8/28/20252.19 EUR
8/27/20252.21 EUR
8/26/20252.20 EUR
8/25/20252.25 EUR
8/21/20252.21 EUR
8/20/20252.14 EUR
8/19/20252.03 EUR
8/18/20252.12 EUR
8/14/20252.02 EUR
8/13/20252.02 EUR
8/12/20251.91 EUR
8/11/20251.89 EUR
8/7/20252.05 EUR
Access this data via the Eulerpool API
Get Free API Key

ProQR Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
4.80 M EUR
-64.72 M EUR
-65.11 M EUR
Jan 1, 2023
9.53 M EUR
-31.86 M EUR
-28.12 M EUR
Jan 1, 2024
19.55 M EUR
-30.47 M EUR
-27.76 M EUR
Jan 1, 2025 (e)
16.24 M EUR
-16.24 M EUR
-42.82 M EUR
Jan 1, 2026 (e)
13.34 M EUR
-13.34 M EUR
-48.25 M EUR
Jan 1, 2027 (e)
17.99 M EUR
-17.99 M EUR
-52.74 M EUR
Jan 1, 2028 (e)
42.87 M EUR
-42.87 M EUR
-36.41 M EUR
Jan 1, 2029 (e)
66.60 M EUR
-66.60 M EUR
-41.67 M EUR

ProQR Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 8:28 PM
 
REVENUEM EUR
REVENUE GROWTH%
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
2016201720182019202020212022202320242025e2026e2027e2028e2029e2030e2031e
1.001.005.001.009.002.004.009.0019.0016.0013.0017.0042.0066.00141.00245.00
-66.67–400.00-80.00800.00-77.78100.00125.00111.11-15.79-18.7530.77147.0657.14113.6473.76
-39.00-40.00-36.00-57.00-42.00-57.00-64.00-31.00-30.00-16.00-13.00-17.00-42.00-66.00-141.00–
-3,900.00-4,000.00-720.00-5,700.00-466.67-2,850.00-1,600.00-344.44-157.89-100.00-100.00-100.00-100.00-100.00-100.00–
-39.00-43.00-36.00-56.00-46.00-61.00-65.00-28.00-27.00-42.00-48.00-52.00-36.00-41.00-15.00–
95.0010.26-16.2855.56-17.8632.616.56-56.92-3.5755.5614.298.33-30.7713.89-63.41–
23.3525.3734.0541.0450.0664.1871.6481.0186.0986.0986.0986.0986.0986.0986.0986.09
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales ProQR Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue ProQR Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare ProQR Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares ProQR Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against ProQR Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

ProQR Therapeutics stock margins

The ProQR Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ProQR Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ProQR Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
0.00 %
-448.36 %
-492.80 %
Jan 1, 2021
0.00 %
-2,382.92 %
-2,567.50 %
Jan 1, 2022
0.00 %
-1,348.33 %
-1,356.46 %
Jan 1, 2023
0.00 %
-334.48 %
-295.21 %
Jan 1, 2024
0.00 %
-155.91 %
-142.05 %
Jan 1, 2025 (e)
0.00 %
-100.00 %
-263.60 %
Jan 1, 2026 (e)
0.00 %
-100.00 %
-361.75 %
Jan 1, 2027 (e)
0.00 %
-100.00 %
-293.09 %

ProQR Therapeutics Stock Revenue, EBIT, Earnings per Share

The ProQR Therapeutics earnings per share therefore indicates how much revenue ProQR Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.19 EUR
-0.85 EUR
-0.93 EUR
Jan 1, 2021
0.04 EUR
-0.89 EUR
-0.96 EUR
Jan 1, 2022
0.07 EUR
-0.90 EUR
-0.91 EUR
Jan 1, 2023
0.12 EUR
-0.39 EUR
-0.35 EUR
Jan 1, 2024
0.23 EUR
-0.35 EUR
-0.32 EUR
Jan 1, 2025 (e)
0.15 EUR
-0.19 EUR
-0.41 EUR
Jan 1, 2026 (e)
0.13 EUR
-0.15 EUR
-0.46 EUR
Jan 1, 2027 (e)
0.17 EUR
-0.21 EUR
-0.50 EUR

ProQR Therapeutics business model & stock analysis

ProQR Therapeutics NV is a Dutch biotechnology company focused on the production of RNA medications for the treatment of genetic diseases. The company was founded in 2012 by Daniel de Boer, Dinko Valerio, and Gerard Platenburg. Since its IPO in 2014, the company has been listed on the NASDAQ. ProQR utilizes a technology called RNA therapeutics, which consists of RNA and offers an alternative treatment method, especially for genetic diseases. Thanks to RNA medications, it is possible to repair faulty mRNA sequences and correct gene expression. This can help fight diseases caused by defective genes, including previously considered incurable diseases. The company works closely with researchers and doctors to develop innovative therapies that truly help patients. Their focus is on diseases that have not been treatable or have a low cure rate in conventional medicine. Diseases that ProQR deals with include cystic fibrosis, inherited retinal diseases, inherited amyloidosis, cancer treatment, and rare genetic diseases. Cystic fibrosis, also known as CF, is one of the most well-known diseases that the company treats. This disease mainly affects children and young adults. Cystic fibrosis is caused by a mutation of the CFTR gene, which disrupts the salt-water balance in the lungs and pancreas. ProQR has developed an RNA therapy called QR-010, which aims to repair the function of the CFTR gene and alleviate the lungs and pancreas. ProQR works closely with clinics to treat patients with this therapy. The company also has RNA medications in the pipeline that help with inherited retinal diseases. One of these diseases is retinitis pigmentosa, which kills the retina and can lead to blindness. ProQR is developing a drug called QR-421a, which is intended to improve vision. The company hopes that the drug will soon be on the market and help patients with retinitis pigmentosa. ProQR is also working on the development of RNA medications to combat rare genetic diseases. This includes the treatment of amyloidosis, a disease in which abnormal proteins accumulate in the body and cause damage. RNA medications could help interrupt the production of abnormal proteins, thereby minimizing damage in the body. ProQR is also working on RNA therapy for cancer. The company focuses on developing medications to combat genetically caused cancer, particularly tumors caused by the loss of heterozygosity (LOH). These tumors can be treated with RNA medications targeting correct gene expression. ProQR Therapeutics NV has had an impressive success story in recent years. The company holds several patents on RNA therapeutics and has built an excellent reputation as a biotechnology company. ProQR's RNA therapies have the potential to successfully treat many genetic diseases that are not possible with conventional medicine. They represent a source of hope for many patients, especially those with cystic fibrosis. The company will continue to develop new RNA therapeutics to treat rare genetic diseases that have been difficult to fight.

ProQR Therapeutics SWOT Analysis

Strengths

ProQR Therapeutics NV has several strengths that contribute to its success in the biopharmaceutical industry. These strengths include:

  • Cutting-edge technology platform allowing efficient development of RNA-based therapeutics.
  • Strong intellectual property portfolio protecting its innovative products.
  • Experienced and skilled management team with a track record of successful drug development.
  • Collaborations with leading academic institutions and pharmaceutical companies, enabling access to knowledge and resources.

Weaknesses

Despite its strengths, ProQR Therapeutics NV also faces certain weaknesses that can pose challenges to its growth and competitiveness:

  • Reliance on a relatively small pipeline with limited product diversity.
  • Dependency on external funding sources for research and development activities.
  • Highly regulated industry, resulting in lengthy and costly drug development processes.
  • Limited market access and potential competition from larger, well-established pharmaceutical companies.

Opportunities

ProQR Therapeutics NV can leverage various opportunities in the market to enhance its growth and market position:

  • Increasing demand for targeted and personalized therapies, aligning with the company's RNA-based platform.
  • Expanding partnerships and collaborations to access new technologies, expertise, and potential funding.
  • Advancements in RNA-based therapeutics and gene therapies, opening up new treatment possibilities.
  • Growing prevalence of genetic diseases and disorders, creating a larger patient population for ProQR's products.

Threats

ProQR Therapeutics NV faces certain threats that could impact its business operations and market performance:

  • Intense competition from other biopharmaceutical companies developing similar RNA-based therapies.
  • Stringent regulatory requirements and potential delays in obtaining approvals for new drugs.
  • Uncertainties in intellectual property protection, potential patent disputes, and generic competition.
  • Volatility and unpredictability of financial markets, affecting the ability to secure funding for research and development.

ProQR Therapeutics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

ProQR Therapeutics Employees
Details
Date
ProQR Therapeutics Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

ProQR Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

ProQR Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

ProQR Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

ProQR Therapeutics shares outstanding

The number of shares of ProQR Therapeutics was 86.09 M in 2025. This indicates how many shares ProQR Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
50.06 M Stocks
Jan 1, 2021
64.18 M Stocks
Jan 1, 2022
71.64 M Stocks
Jan 1, 2023
81.01 M Stocks
Jan 1, 2024
86.09 M Stocks
Jan 1, 2025 (e)
86.09 M Stocks
Jan 1, 2026 (e)
86.09 M Stocks
Jan 1, 2027 (e)
86.09 M Stocks

Current ProQR Therapeutics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
93.33 % (14)
Hold
6.67 % (1)
Sell
0.00 % (0)
12M Price Target
8.39
Last Price
1.78
Currency
EUR
12M Return Potential
371.26 %
LTM Return
0 %

ProQR Therapeutics Analyst Rating Actions

DateFirmActionRatingReliability
6/29/2026
Evercore ISI Group
Evercore ISI Group
MaintainedOutperform62
6/26/2026
Jones Trading
Jones Trading
MaintainedBuy–
6/26/2026
Chardan Capital
Chardan Capital
MaintainedBuy–
4/9/2026
Chardan Capital
Chardan Capital
MaintainedBuy–
11/4/2025
Chardan Capital
Chardan Capital
MaintainedBuy–
8/8/2025
Chardan Capital
Chardan Capital
MaintainedBuy–
6/27/2025
JMP Securities
JMP Securities
MaintainedMarket Outperform–
6/27/2025
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
5/13/2025
Oppenheimer
Oppenheimer
MaintainedOutperform65
3/14/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

ProQR Therapeutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/5/2026-0.12EUR-4.67 MEUR-2026 Q2
5/6/2026-0.12EUR-3.86 MEUR-2026 Q1
2/19/2026-0.10EUR-3.88 MEUR-2025 Q4
5/14/2024-0.09EUR-3.56 MEUR-2024 Q1
3/27/20240.01EUR-9.77 MEUR-2023 Q4
11/7/2023-0.11EUR-1.62 MEUR-2023 Q3
8/2/2023-0.18EUR-925,679.00EUR-2023 Q2
5/3/2023-0.17EUR-925,679.00EUR-2023 Q1
2/22/2023-0.18EUR-953,074.00EUR-2022 Q4
11/9/2022-0.21EUR-851,574.00EUR-2022 Q3

EESG©

Eulerpool ESG Scorecard© for the ProQR Therapeutics stock

62/100
62
Environment
99
Social
25
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees62
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

ProQR Therapeutics shareholder structure

% Name
13.60198%
Van Herk Investments
Van Herk Investments
6.26667%
Adage Capital Management, L.P.
Adage Capital Management, L.P.
4.74377%
Privium Fund Management BV
Privium Fund Management BV
3.32180%
Affinity Asset Advisors LLC
Affinity Asset Advisors LLC
2.90845%
Morgan Stanley & Co. LLC
Morgan Stanley & Co. LLC
1.96976%
Sio Capital Management, LLC
Sio Capital Management, LLC
...

ProQR Therapeutics Beneficial Ownership Filings (SEC 13D/G)

Free Float
61.1%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
10.90%
Van Herk Private Equity Investments B.V.
Van Herk Private Equity Investments B.V.
SEC ↗
10.90%
Van Herk Management Services B.V.
Van Herk Management Services B.V.
SEC ↗
10.90%
Van Herk Investments THI B.V.
Van Herk Investments THI B.V.
SEC ↗
10.90%
Stichting Administratiekantoor Penulata
Stichting Administratiekantoor Penulata
SEC ↗
10.90%
Stichting Administratiekantoor Abchrys
Stichting Administratiekantoor Abchrys
SEC ↗
10.90%
Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V.
Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V.
SEC ↗
10.90%
A. van Herk Holding B.V.
A. van Herk Holding B.V.
SEC ↗
10.90%
Adrianus van Herk
Adrianus van Herk
SEC ↗
10.78%
Wellington Management Group LLP
Wellington Management Group LLP
SEC ↗
6.80%
Patrick Johan Hendrik Krol
Patrick Johan Hendrik Krol
SEC ↗

ProQR Therapeutics Executives and Management Board

14 members · avg. age 57 · 43 % women

DB

Mr. Daniel de Boer (41)

Chief Executive Officer, Founder, Executive Director · since 2012

1.83 M EUR

Management

RB

Mr. Rene Beukema (60)

Chief Corporate Development Officer, General Counsel, Executive Director

980,000.00 EUR
GP

Mr. Gerard Platenburg (61)

Chief Scientific Officer, Executive Director · since 2014

488,000.00 EUR
DH

Mr. Dennis Hom

Chief Financial Officer

–
SS

Ms. Sheila Sponselee (40)

Chief People and Operations Officer

–
CL

Dr. Cristina Lopez

Chief Medical Officer

–
SK

Ms. Sarah Kiely

Vice President - Investor Relations and Corporate Communications · since 2020

–

Board of Directors

TH

Ms. Theresa Heggie (64)

Non-Executive Director · since 2019

175,000.00 EUR
JS

Dr. James Shannon (68)

Independent Non-Executive Chairman of the Board

122,000.00 EUR
DV

Mr. Dinko Valerio (68)

Non-Executive Director · since 2014

107,000.00 EUR
BF

Mr. Bart Filius (54)

Non-Executive Independent Director

100,000.00 EUR
AL

Ms. Alison Lawton (63)

Non-Executive Independent Director

99,000.00 EUR
BC

Ms. Begona Carreno (53)

Non-Executive Independent Director

77,000.00 EUR

Frequently asked questions about ProQR Therapeutics

The business model of ProQR Therapeutics NV is centered around developing RNA-based therapeutics to treat rare and genetic diseases. By utilizing proprietary RNA repair technologies, the company aims to target specific genetic defects and correct them at the molecular level. ProQR Therapeutics NV conducts extensive research and clinical trials to develop innovative treatments for various conditions, including cystic fibrosis, Leber's congenital amaurosis, and rare forms of genetic blindness. Through strategic partnerships, they aim to advance their pipeline of candidate therapies and ultimately improve the lives of patients affected by these diseases.

ProQR Therapeutics NV is primarily active in the biotechnology industry.

The main competitors of ProQR Therapeutics NV in the market are Editas Medicine, Ionis Pharmaceuticals, and Vertex Pharmaceuticals.

ProQR Therapeutics NV is a leading biotech company focused on developing innovative RNA-based therapies to treat genetic diseases. Founded in 2012 and headquartered in the Netherlands, ProQR pioneers the development of RNA therapies by leveraging a proprietary technology platform. The company's objective is to address the root cause of diseases at the genetic level, aiming to transform the lives of patients with severe genetic disorders. ProQR's pipeline comprises targeted therapies for a variety of indications, including rare eye diseases, cystic fibrosis, and genetic muscle disorders. With its commitment to advancing groundbreaking treatments, ProQR Therapeutics NV stands at the forefront of biotech innovation.

ProQR Therapeutics NV, a leading biopharmaceutical company, has achieved several significant milestones. Notably, the company successfully completed a Phase 1b clinical trial for its Usher syndrome therapy, QR-421a. It also advanced its RNA therapeutics for cystic fibrosis (QR-010) into Phase 2 trials, showcasing promising results. ProQR Therapeutics NV received Fast Track designation from the U.S. FDA for its Leber Congenital Amaurosis program (QR-110), accelerating its development. Moreover, the company's QR-313 therapeutic, targeting dystrophic epidermolysis bullosa, obtained Orphan Drug designation from the FDA and European Medicines Agency. ProQR Therapeutics NV's commitment to innovative solutions and achieving significant clinical milestones positions it favorably in the pharmaceutical industry.

ProQR Therapeutics NV is primarily present in multiple countries and regions globally. The company has a strong presence in Europe, with headquarters in the Netherlands. It operates extensively within the European Union, including countries like Germany, France, and the United Kingdom. ProQR has also expanded its reach into North America, specifically the United States. Additionally, the company has established a presence in various international markets, such as Japan. ProQR Therapeutics NV's global presence allows it to access diverse markets and collaborate with partners worldwide to advance its innovative therapies and treatments.

ProQR Therapeutics NV is committed to transforming the lives of patients with severe genetic diseases. Their corporate philosophy revolves around innovation, collaboration, and dedication to scientific excellence. With a focus on RNA therapies, ProQR Therapeutics NV aims to develop life-changing treatments using proprietary technologies and expertise. Their values include patient-centricity, integrity, and a strong sense of responsibility towards their stakeholders. By leveraging their extensive knowledge and strategic partnerships, ProQR Therapeutics NV strives to address unmet medical needs and improve the quality of life for individuals affected by genetic disorders.

Analysts currently set an average price target of 8.50 EUR for the ProQR Therapeutics stock (median: 8.39 EUR), implying +377.5 % versus the latest price. The consensus is based on 15 analyst ratings.

ProQR Therapeutics Analyst Price Targets 2026

15 analysts currently rate the ProQR Therapeutics stock: 14 recommend buying, 1 holding and 0 selling. For 2026, analysts expect ProQR Therapeutics to generate revenue of 13.34 M EUR and earnings per share of -0.56 EUR.

ProQR Therapeutics Analyst Price Targets 2026

The ProQR Therapeutics share (PRQR) is listed on 4 stock exchanges, including: NASDAQ (PRQR), Frankfurt (0PQ.F), München (0PQ.MU), Düsseldorf (0PQ.DU).

ProQR Therapeutics NV is a biopharmaceutical company that focuses on RNA-based therapeutics for the treatment of genetically inherited diseases. With over a decade of company history, it has become one of the leading companies in the field of RNA medicine. The business model of ProQR Therapeutics NV is based on the discovery, development, and commercialization of RNA technologies and products. With a strong focus on identifying genetic mutations that lead to diseases, the company focuses on developing RNA-based therapies to treat these diseases. One area that the company focuses on is ophthalmological research. ProQR Therapeutics NV has established itself as a pioneer in RNA medicine for the treatment of eye diseases. The company has developed an RNA technology platform called "Axiomer" specifically to enable the treatment of retinal diseases. Another area that ProQR Therapeutics NV focuses on is pulmonary research. The company hopes to provide life-changing treatments for patients with cystic fibrosis and other pulmonary diseases through RNA therapies. The company also has a strong presence in nephrology. An RNA therapeutic has been developed to treat IQ motif-containing GTPase-activating protein 2 (IQGAP2), which is a key factor in the development of a rare and severe progressive kidney disease called ADPKD (autosomal dominant polycystic kidney disease). In addition, the company works closely with leading research and development institutions to further develop and improve RNA technologies. ProQR Therapeutics NV has partnerships with various renowned institutions, including the National Institutes of Health (NIH), the Cystic Fibrosis Foundation, and the Usher Syndrome Coalition Program. The company has already developed several RNA therapeutics and is bringing these products to market. One such product is QR-010, for which ProQR Therapeutics NV has received an Orphan Drug Designation. The medication is intended for patients with cystic fibrosis and is currently in clinical phase 2b/3. Another product, QR-313, is also in clinical phase for patients with epidermolytic ichthyosis. In addition to these RNA therapeutics, the company also has a robust pipeline for further RNA-based therapies in various stages of development. The company plans to bring these products to market in the coming years. Overall, ProQR Therapeutics NV has a solid business model based on innovative RNA technologies and the development of life-changing therapies for patients with rare and severe diseases. With a strong presence in ophthalmology, nephrology, and pulmonology, and a wide range of RNA products in development, the company seems well-positioned to continue its growth in the coming years.

The expected revenue of ProQR Therapeutics is 13.34 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of ProQR Therapeutics is -48.25 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of ProQR Therapeutics is currently -3.18. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ProQR Therapeutics stock.

The price-to-sales ratio (P/S) of ProQR Therapeutics is currently 11.49. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ProQR Therapeutics stock.

The Eulerpool Quality Score for ProQR Therapeutics is 3/10.

The ISIN of ProQR Therapeutics is NL0010872495. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of ProQR Therapeutics is A12B97. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of ProQR Therapeutics is PRQR. The ticker symbol is used to trade ProQR Therapeutics shares on the stock exchange.

ProQR Therapeutics paid dividends every year for the past 0 years.

ProQR Therapeutics is assigned to the 'Health' sector.

The dividends of ProQR Therapeutics are distributed in EUR.

All fundamentals and in-depth analysis of ProQR Therapeutics

Our stock analysis for ProQR Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ProQR Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

ProQR Therapeutics Stock
ProQR Therapeutics Revenue→
ProQR Therapeutics Stock
ProQR Therapeutics Net Income→
ProQR Therapeutics Stock
ProQR Therapeutics P/E→
ProQR Therapeutics Stock
ProQR Therapeutics P/S→
ProQR Therapeutics Stock
ProQR Therapeutics EBIT→
ProQR Therapeutics Stock
ProQR Therapeutics Dividend→
ProQR Therapeutics Stock
ProQR Therapeutics Directors Dealings→
ProQR Therapeutics Stock
ProQR Therapeutics Stocks→
ProQR Therapeutics Stock
ProQR Therapeutics Market capitalization→
ProQR Therapeutics Stock
ProQR Therapeutics Debt→
ProQR Therapeutics Stock
ProQR Therapeutics Liabilities→
ProQR Therapeutics Stock
ProQR Therapeutics Equity→
ProQR Therapeutics Stock
ProQR Therapeutics AAQS→
ProQR Therapeutics Stock
ProQR Therapeutics Employees→
ProQR Therapeutics Stock
ProQR Therapeutics ROE→
ProQR Therapeutics Stock
ProQR Therapeutics ROA→
ProQR Therapeutics Stock
ProQR Therapeutics ROCE→
ProQR Therapeutics Stock
ProQR Therapeutics News→
ProQR Therapeutics Stock
ProQR Therapeutics Analyst Price Targets→

Health Stocks

Prostatype GenomicsProphase LabsProtagenic TherapeuticsPropanc BiopharmaProtagonist TherapeuticsPromisia HealthcareProtalix BiotherapeuticsProMIS NeurosciencesProtara TherapeuticsPromimicProtect Pharmaceutical CorporationProkidneyAll Stocks A–Z →